Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q1 2022 · 10-Q
Revenue$0.00$0.00— vs Q1 2021 Net Income-$2.03M-$2.03MN/M vs Q1 2021 EPS, diluted—
Operating Income-$2,026,515N/M Operating Cash Flow-$2,861,649N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end